SuperGen's decitabine may reverse MDR
SuperGen's investigational anticancer drug decitabine has been shown inpreclinical studies to restore some susceptibility to chemotherapy in multidrug-resistant ovarian and colon cancer cells. The studies have been presented at the Genomic Regulation and Cancer Conference held in Glasgow, Scotland.
Several key genes that allow cancer cells to be responsive to chemotherapy are switched off by a process called DNA methylation, commented Joseph Rubinfeld, SuperGen's chief executive. Decitabine's mode of action, the regulation of DNA methylation, is thought to allow these genes to be switched back on.
"We have long believed that decitabine, currently in Phase III clinical studies for the treatment of advanced myelodysplastic syndrome, could be a multi-platform drug with uses beyond the traditional chemotherapeutic approach," said Dr Rubinfeld, adding that a Phase I study of decitabine in chemotherapy-resistant ovarian and colon cancers is due to start before the end of the year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze